Targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2): Latest Insights on Synthetic Strategies

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Vascular endothelial growth factor receptor 2 (VEGFR-2) is essential for angiogenesis and cancer progression.
• Tumor-induced angiogenesis relies on VEGFR-2 signaling, making it a key target for anticancer therapies.
• Current VEGFR-2 inhibitors face challenges including drug resistance, off-target effects, and adverse side effects.

Purpose of the Study:

• To review recent advancements in the development of novel VEGFR-2 inhibitors.
• To explore new drug candidates with promising antiproliferative and VEGFR-2 inhibitory activities.
• To organize these novel inhibitors based on their key structural features.

Main Methods:

• Literature review of recent studies on VEGFR-2 inhibitors.
• Analysis of synthesis strategies for novel drug candidates.
• Categorization of inhibitors based on shared structural motifs derived from clinically used drugs.

Main Results:

• Identification of novel chemical entities with significant VEGFR-2 inhibitory potential.
• Synthesis of new drug candidates incorporating key structural features of existing inhibitors.
• Demonstration of promising antiproliferative activity in preclinical models.

Conclusions:

• Novel VEGFR-2 inhibitors are being actively developed to address limitations of current therapies.
• Structural modifications of known inhibitors offer a viable strategy for discovering new anticancer agents.
• Continued research in this area holds promise for more effective cancer treatments.